TSI Corporation

Milford, MA 01757

SBIR Award Summary

Total Number of Awards 12
Total Value of Awards $0.0
First Award Date 12/15/88
Most Recent Award Date 09/30/95

Key Personnel

Last Name Name Awards Contact
Smith Gilbert L Smith 1
Reddy Vemuri Reddy 5
Collas Philippe Collas 1
Wei Chamer Wei 1
Snyder Benjamin Snyder 1
Dobrinsky John Dobrinsky 1
Poole Trent A Poole 1
Vitale James Vitale 1

12 Awards Won

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/95 - 05/31/97

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/92 - 07/31/93

Human growth hormone (hGH) is an important therapeutic being produced at high cost by recombinant methods. The Phase I of this SBIR has demonstrated the feasibility of producing this hormone in the milk of transgenic mice. The present aim is to produce hGH in the milk of transgenic rabbits which are easy and economical to handle. Transgenic r...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/92 - 08/31/92

Biosensors that could monitor interactions between biologically-active compounds and a target receptor would facilitate the process of drug discovery. The proposed study will test the feasibility of using a capacitive sensor based on an interdigitated electrode array to monitor the interaction of volatile anesthetics and calcium channel antagon...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/91 - 09/29/92

The objective of this Phase II proposal is to optimize a procedure for producing a large number of genetically identical rabbits by serial nuclear transplantation. The use of genetically identical rabbits would decrease the number of animals needed for experimentation. Development of a highly efficient nuclear cloning strategy will make it com...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/91 - 04/30/92

Human growth hormone (hGH) is an important therapeutic being produced at high cost by recombinant methods. The Phase I of this SBIR has demonstrated the feasibility of producing this hormone in the milk of transgenic mice. The present aim is to produce hGH in the milk of transgenic rabbits which are easy and economical to handle. Transgenic r...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/24/90 - 03/23/91

Aids (sic) is a fatal disease caused by human innumodeficiency virus (HIV). During the life cycle of HIV, its reverse transcriptase is an essential enzyme required for its replication. Therefore, it is an excellent target for anti-HIV therapeutics; and extensive effort is focused on searching for its inhibitors. This is hindered, because HIV i...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/90 - 02/28/91

TSI proposes to develop a transgenic mouse model for Alzheimer's Disease (AD), a devastating degenerative disorder of the brain that is the leading cause of dementia among the elderly. AD is characterized by cerebrovascular amyloid deposits, endocortical plaques and neurofibrillary tangles. The predominant component of these structures is b-amyl...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/90 - 02/28/91

AIDS is a fatal disease caused by human immunodeficiency virus type 1 (HIV- 1). A big stumbling block to the development of effective vaccines and therapeutics for AIDS is the lack of suitable animal model. Therefore, there is an urgent need to search for a common laboratory animal to be developed as an AIDS model. Recently two groups, one le...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/90 - 08/31/90

Transgenic mouse technology provides a powerful biological assay for studying oncogene expression and activity in whole tissue and organ development. Embryo vitrification technology allows a researcher to store transgenic mouse embryos for future studies and distribution, enabling more researchers the opportunity to use these important experime...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/89 - 03/31/90

Soluble CD4 is considered to have a great potential in AIDS therapy including treatment and prevention of AIDS. In vitro studies have estimated that a large excess (1000:1) of soluble CD4 is needed to achieve a significant reduction in infectious particles. It is likely that an excess of soluble CD4 is needed constantly over prolonged periods ...

Load More